‘Generic Drugs Market Worth $384.0bn In 2021’ Says Visiongain Report

29 August 2018
Pharma

Visiongain’s new report Generic Drugs Market Forecast 2017-2027: Growth in Leading Regional and National Markets – US, EU5, Asia-Pacific, Emerging Markets indicates that the generic drugs market will see $384.0bn in spending in 2021.

The generic drugs market is expected to grow at a CAGR of 8.8% in the first half of the forecast period and CAGR of 7.0% in the second half of the forecast period. The market is expected to grow at a CAGR of 7.9% from 2015 to 2027. The market is estimated at $254.6bn in 2016, $384.0bn in 2021, and $574.7bn in 2027.

The lead analyst of the report said: “The global generics market is assured of good growth rates and high revenues. Drivers in this market include the continual assistance of governments in promoting the use of generics as a mean to cut healthcare costs and the perpetual loss of patents of high earning branded pharmaceuticals. Other drivers include an increase in the ageing population who are most likely to become ill and will therefore demand cheap and effective drugs, generic or otherwise. However, a major concern to generic companies has to be the high level of competition within this market which will inevitably lead to lower prices and overall profitability. A general trend in response to this will be a higher level of merger and acquisitions between generic companies.

In a further response to this competition there will be an increasingly number of generic companies who will be investing in the production of their own branded patentable drugs. However, the future of the generics market, whatever form it takes, will continue to be lucrative and very attractive“

The 303 page report contains 89 tables and 87 charts that add visual analysis in order to explain the developing trends within the Generic Drugs Market. Visiongain provides revenue forecasts for the period 2017-2027.

The 303 page report offers market forecasts and analysis for 14 leading national markets: US, Japan, Germany, UK, France, Spain, Italy, Brazil, Russia, China, India, South Korea, Mexico and Turkey. In addition, the report contains a dedicated leading companies’ chapter covering companies leading the field in the generic drugs market.

The Generic Drugs Market Forecast 2017-2027: Growth in Leading Regional and National Markets – US, EU5, Asia-Pacific, Emerging Markets report will be of value to anyone who wants to better understand the Generic Drugs market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the Generic Drugs industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever